Refine
Has Fulltext
- yes (32)
Is part of the Bibliography
- yes (32)
Year of publication
- 2013 (32) (remove)
Document Type
- Journal article (29)
- Doctoral Thesis (3)
Language
- English (32) (remove)
Keywords
- cytokines (3)
- heart failure (3)
- mortality (3)
- myocardial infarction (3)
- prognosis (3)
- Fabry disease (2)
- cardiac hypertrophy (2)
- cardiovascular disease (2)
- cardiovascular diseases (2)
- cardiovascular events (2)
- chronic kidney disease (2)
- cognitive decline (2)
- enzyme replacement therapy (2)
- hemodialysis (2)
- inflammation (2)
- postmenopausal women (2)
- risk factors (2)
- sudden cardiac death (2)
- A-delta fibers (1)
- Addisons disease (1)
- Arteriosklerose (1)
- Atherosklerose (1)
- Biokompatibilität (1)
- Bioluminescence (1)
- Blut (1)
- Ca2+i handling (1)
- Calibration (1)
- Cardiac magnetic resonance imaging (1)
- Cell (1)
- Clinical prediction rule (1)
- DHEA (1)
- DHEA-Sulfotransferase (1)
- Dehydroepiandrosteron (1)
- Extracorporeal membrane oxygenation (1)
- Fabry (1)
- Fabry nephropathy (1)
- Fabry patient (1)
- False positive reactions (1)
- GLA protein UCMGP (1)
- GMPcGMP-dependent protein kinase I (1)
- Hämodiafiltration (1)
- Hämodialyse (1)
- Infection control (1)
- Ionenstärke (1)
- Ionic strength (1)
- Kontrastmittel (1)
- L-arginine (1)
- LV mass (1)
- Lyso-Gb3 (1)
- Methicillin-resistant staphylococcus aureus (1)
- Myocardial infarction (1)
- Nrf2 (1)
- PAPSS2 (1)
- Pain-related evoked potentials (1)
- Phosphoadenosinphosphosulfat (1)
- Predictive value of tests (1)
- Proteinbindung (1)
- Small fiber neuropathy (1)
- Superparamagnetische Eisenoxid Kontrastmittel (1)
- T cells (1)
- Toxin (1)
- United States (1)
- Urämie (1)
- Urämietoxine (1)
- VCAM (1)
- Ventricular septal rupture (1)
- Zelllinie (1)
- adenomas (1)
- adrenal (1)
- adult patients (1)
- agalsidase-beta (1)
- aging (1)
- aldosterone (1)
- alkaline phosphatase (1)
- alpha-galactosidase-A (1)
- amyloidosis (1)
- anxiety (1)
- aorta (1)
- aortic valve (1)
- aortic valve disease (1)
- apoptosis (1)
- atherosclerosis (1)
- bardoxolone methyl (1)
- biocompatibility (1)
- biopsy findings (1)
- blood (1)
- blood pressure (1)
- blood-glucose control (1)
- body weight (1)
- bone formation (1)
- bone mineral density (1)
- brain natriuretic peptide (1)
- calcium (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinomas (1)
- cardiac energy metabolism (1)
- cardiac transplantation (1)
- cardiac ventricles (1)
- cardiovascular care (1)
- cardiovascular death (1)
- cardiovascular magnetic-resonance (1)
- cardiovascular morbidity (1)
- cell lines (1)
- cell staining (1)
- central nervous system (1)
- chromosomes (1)
- chronic kidney-disease (1)
- circadian therapy (1)
- clinical trial (1)
- cognitive impairment (1)
- computed tomography (1)
- cornea verticillata (1)
- coronary calcification (1)
- coronary-artery calcification (1)
- cortisol (1)
- creatine synthesis (1)
- cyclic (1)
- deformation (1)
- depression (1)
- diabetes complications (1)
- diabetes mellitus (1)
- diabetes mellitus type 2 (1)
- diabetic mouse (1)
- diabetic nephropathy (1)
- dialysis (1)
- echocardiography (1)
- ejection fraction (1)
- end stage renal disease (1)
- end-stage renal disease (1)
- epidemiology (1)
- extracellular matrix (1)
- extracellular matrix remodeling (1)
- fall (1)
- fetuin A (1)
- fibrosis (1)
- focal semental glomerulosclerosis (1)
- fracture (1)
- genetic loci (1)
- genetics (1)
- genome-wide association (1)
- glomerular filtration rate (1)
- glomerular-filtration-rate (1)
- glucocorticoid replacement regimens (1)
- health care research (1)
- health questionnaire (1)
- heart (1)
- heart rate (1)
- heodialysis patients (1)
- homeostasis (1)
- hospitalization (1)
- hypertrophic cardiomyopathy (1)
- hypopituitary patients (1)
- immune cells (1)
- immuno-modulation (1)
- induced insulin-release (1)
- iron oxide contrast agent (1)
- kidney (1)
- kidney disease (1)
- kidney-disease CKD (1)
- kidneys (1)
- laxative (1)
- left ventricular mass (1)
- left-ventricular hypertrophy (1)
- lipoxygenase (1)
- magnetic resonance imaging (1)
- malignant tumors (1)
- medicine (1)
- metastasis (1)
- mineral metabolism (1)
- modified-release hydrocortisone (1)
- mouse (1)
- myocardium (1)
- natriuretic peptide (1)
- natural-history data (1)
- neurons (1)
- neutrophils (1)
- nictric-oxide (1)
- non-triggered (1)
- notch signaling (1)
- observational study (1)
- outcomes (1)
- phase-contrast CMR (1)
- podocyte (1)
- population (1)
- premature mortality (1)
- prevalence (1)
- protein binding (1)
- pulse-wave velocity (1)
- quality of life (1)
- radial (1)
- randomized controlled trial (1)
- rat kidney (1)
- regression analysis (1)
- regulatory T cells (1)
- renal fibrosis (1)
- renal function (1)
- renal osteodystrophy (1)
- replacement therapy (1)
- retrospective (1)
- risk (1)
- scale (1)
- sclerostin (1)
- self-gating (1)
- septal hypertrophy (1)
- serum creatinine (1)
- short term (1)
- stage renal-disease (1)
- standardization (1)
- stem cell transplantation (1)
- stroke (1)
- subjective health-status (1)
- superparamagnetische Eisenoxid Kontrastmittel (1)
- surgical and invasive medical procedures (1)
- surgical repair (1)
- task force (1)
- therapeutic management (1)
- treatment (1)
- trial design (1)
- type 2 diabetes (1)
- uremic toxin (1)
- urinary protein excretion (1)
- use (1)
- validation (1)
- validity (1)
- vascular calcification (1)
- vascular cell adhesion molecules (1)
- vascular surgery (1)
- vaskuläre Adhäsionsmoleküle (1)
- α-galactosidase A (1)
Institute
- Medizinische Klinik und Poliklinik I (32) (remove)
Background: Sclerostin is a Wnt pathway antagonist regulating osteoblast activity and bone turnover. Here, we assessed the potential association of sclerostin with the development of coronary artery (CAC) and aortic valve calcifications (AVC) in haemodialysis (HD) patients. Methods: We conducted a cross-sectional multi-slice computed tomography (MS-CT) scanning study in 67 chronic HD patients (59.4 +/- 14.8 yrs) for measurement of CAC and AVC. We tested established biomarkers as well as serum sclerostin (ELISA) regarding their association to the presence of calcification. Fifty-four adults without relevant renal disease served as controls for serum sclerostin levels. Additionally, sclerostin expression in explanted aortic valves from 15 dialysis patients was analysed ex vivo by immunohistochemistry and mRNA quantification (Qt-RT-PCR). Results: CAC (Agatston score > 100) and any AVC were present in 65% and in 40% of the MS-CT patient group, respectively. Serum sclerostin levels (1.53 +/- 0.81 vs 0.76 +/- 0.31 ng/mL, p < 0.001) were significantly elevated in HD compared to controls and more so in HD patients with AVC versus those without AVC (1.78 +/- 0.84 vs 1.35 +/- 0.73 ng/mL, p = 0.02). Multivariable regression analysis for AVC revealed significant associations with higher serum sclerostin. Ex vivo analysis of uraemic calcified aortic valves (n = 10) revealed a strong sclerostin expression very close to calcified regions (no sclerostin staining in non-calcified valves). Correspondingly, we observed a highly significant upregulation of sclerostin mRNA in calcified valves compared to non-calcified control valves. Conclusion: We found a strong association of sclerostin with calcifying aortic heart valve disease in haemodialysis patients. Sclerostin is locally produced in aortic valve tissue adjacent to areas of calcification.
Early healing after myocardial infarction (MI) is characterized by a strong inflammatory reaction. Most leukotrienes are pro-inflammatory and are therefore potential mediators of healing and remodeling after myocardial ischemia. The enzyme 5-lipoxygenase (5-LOX) has a key role in the transformation of arachidonic acid in leukotrienes. Thus, we tested the effect of 5-LOX on healing after MI. After chronic coronary artery ligation, early mortality was significantly increased in 5-LOX\(^{−/−}\) when compared to matching wildtype (WT) mice due to left ventricular rupture. This effect could be reproduced in mice treated with the 5-LOX inhibitor Zileuton. A perfusion mismatch due to the vasoactive potential of leukotrienes is not responsible for left ventricular rupture since local blood flow assessed by magnetic resonance perfusion measurements was not different. However, after MI, there was an accentuation of the inflammatory reaction with an increase of pro-inflammatory macrophages. Yet, mortality was not changed in chimeric mice (WT vs. 5-LOX\(^{−/−}\) bone marrow in 5-LOX\(^{−/−}\) animals), indicating that an altered function of 5-LOX\(^{−/−}\) inflammatory cells is not responsible for the phenotype. Collagen production and accumulation of fibroblasts were significantly reduced in 5-LOX\(^{−/−}\) mice in vivo after MI. This might be due to an impaired migration of 5-LOX\(^{−/−}\) fibroblasts, as shown in vitro to serum. In conclusion, a lack or inhibition of 5-LOX increases mortality after MI because of healing defects. This is not mediated by a change in local blood flow, but through an altered inflammation and/or fibroblast function.